Size: | Price | Quantity | |
---|---|---|---|
10 mg | $40.00 | ||
50 mg | $100.00 |
Sildenafil citrate (171599-83-0) is a potent and selective phosphodiesterase (PDE5) inhibitor, IC50=4 nM).1-3 Clinically useful agent for male erectile disfunction4 and pulmonary hypertension5.
References/Citations:
1) Terrett et al. (1996), Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction; Bioorg. Med. Chem. Lett., 6 1819
2) Ballard et al. (1998), Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes; J. Urol., 159 2164
3) Turko et al. (1999), Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds; Mol. Pharmacol., 56 124
4) Teixeira et al. (2006), Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta; J. Pharmacol. Exp. Therap., 316 654
5) Ghofrani et al. (2006), Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond; Nat. Rev. Drug Discov., 5 689
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Sildenafil citrate (171599-83-0) is a potent and selective phosphodiesterase (PDE5) inhibitor, IC50=4 nM).1-3 Clinically useful agent for male erectile disfunction4 and pulmonary hypertension5.
References/Citations:
1) Terrett et al. (1996), Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction; Bioorg. Med. Chem. Lett., 6 1819
2) Ballard et al. (1998), Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes; J. Urol., 159 2164
3) Turko et al. (1999), Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds; Mol. Pharmacol., 56 124
4) Teixeira et al. (2006), Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta; J. Pharmacol. Exp. Therap., 316 654
5) Ghofrani et al. (2006), Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond; Nat. Rev. Drug Discov., 5 689
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.